Long-Term Follow-Up of COVID-19 Convalescents—Immune Response Associated with Reinfection Rate and Symptoms.

Authors: Seller, Anna^1,2,3 (AUTHOR), Hackenbruch, Christopher^1,3 (AUTHOR), Walz, Juliane S.^1,3,4 (AUTHOR), Nelde, Annika^3,4 (AUTHOR), Heitmann, Jonas S.^1,3,4 (AUTHOR) jonas.heitmann@med.uni-tuebingen.de

Source: Viruses (1999-4915). Oct2023, Vol. 15 Issue 10, p2100. 16p.

Subject Terms: *POST-acute COVID-19 syndrome, *IMMUNE response, *COVID-19, *REINFECTION, *SYMPTOMS, *IMMUNOGLOBULINS

AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.

Authors: Jung, Susanne, Nelde, Annika, Maringer, Yacine, Denk, Monika, Zieschang, Lisa, Kammer, Christine, Özbek, Melek, Martus, Peter, Hackenbruch, Christopher, Englisch, Alexander, Heitmann, Jonas S., Salih, Helmut R., Walz, Juliane S.

Source: Frontiers in Oncology; 2024, p1-9, 9p

Subject Terms: TUMOR antigens, ACUTE myeloid leukemia, MEDICAL societies, BOOSTER vaccines, HLA histocompatibility antigens

Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome.

Authors: Hackenbruch, Christopher^1,2 (AUTHOR), Maringer, Yacine^2,3,4 (AUTHOR), Tegeler, Christian M.^1,5 (AUTHOR), Walz, Juliane S.^1,2,3,4 (AUTHOR), Nelde, Annika^2,3,4 (AUTHOR) annika.nelde@uni-tuebingen.de, Heitmann, Jonas S.^1,2 (AUTHOR)

Source: Viruses (1999-4915). Mar2023, Vol. 15 Issue 3, p701. 15p.

Subject Terms: *POST-acute COVID-19 syndrome, *SARS-CoV-2, *IMMUNOGLOBULINS, *COVID-19, *HUMORAL immunity

iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.

Authors: Englisch, Alexander, Hayn, Clara, Jung, Susanne, Heitmann, Jonas S., Hackenbruch, Christopher, Maringer, Yacine, Nelde, Annika, Wacker, Marcel, Denk, Monika, Zieschang, Lisa, Kammer, Christine, Martus, Peter, Salih, Helmut R., Walz, Juliane S.

Source: Frontiers in Oncology; 2024, p1-10, 10p

Subject Terms: BRUTON tyrosine kinase, CHRONIC lymphocytic leukemia, PEPTIDE vaccines, VACCINE immunogenicity, PROTEIN-tyrosine kinase inhibitors

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

Authors: Hackenbruch, Christopher, Bauer, Jens, Heitmann, Jonas S., Maringer, Yacine, Nelde, Annika, Denk, Monika, Zieschang, Lisa, Kammer, Christine, Federmann, Birgit, Jung, Susanne, Martus, Peter, Malek, Nisar P., Nikolaou, Konstantin, Salih, Helmut R., Bitzer, Michael, Walz, Juliane S.

Source: Frontiers in Oncology; 2024, p1-12, 12p

Subject Terms: FIBROLAMELLAR hepatocellular carcinoma, IMMUNE checkpoint inhibitors, PEPTIDE vaccines, CLINICAL trials, GENE fusion, HEPATITIS B vaccines, APOMORPHINE, PHYLLODES tumors, HEPATOCELLULAR carcinoma

Geographic Terms: MANNHEIM (Germany)

Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3).

Authors: Jung, Susanne, Schlenk, Richard F., Hackenbruch, Christopher, Roldan Pinzon, Sandra S. L., Bitzer, Michael, Pflügler, Martin, Walz, Juliane S., Gundram Jung, Heitmann, Jonas S., Salih, Helmut R.

Source: Frontiers in Oncology; 2024, p01-11, 11p

Subject Terms: BISPECIFIC antibodies, COLORECTAL cancer, MEDICAL ethics, CANCER patients, PATIENTS' attitudes

Geographic Terms: DUSSELDORF (Germany)

People: HEINE, Heinrich, 1797-1856

FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic...

Authors: Bitzer, Michael, Hackenbruch, Christopher, Bauer, Jens, Heitmann, Jonas S., Maringer, Yacine, Nelde, Annika, Salih, Helmut R., Walz, Juliane S.

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, pTPS580-TPS580, 151p

ProSperA: Phase I study to evaluate safety, tolerability and preliminary efficacy of a bispecific PSMAxCD3 antibody in men with biochemical recurrence of prostate cancer.

Authors: Hackenbruch, Christopher, Heitmann, Jonas S., Walz, Juliane S., Federmann, Birgit, Pflügler, Martin, Hadaschik, Boris A., Jung, Gundram, Salih, Helmut R.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS5114-TPS5114, 1p

Clinical development of the bispecific PSMAxCD3 antibody CC-1.

Authors: Hackenbruch, Christopher, Heitmann, Jonas S., Walz, Juliane S., Federmann, Birgit, Pflügler, Martin, Schlenk, Richard F., Ochsenreither, Sebastian, Hadaschik, Boris A., Darr, Christopher, Grünwald, Viktor, Jung, Gundram, Salih, Helmut R.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p2534-2534, 1p

Isolation of T Cells from the Gut.

Authors: Reißig, Sonja, Hackenbruch, Christopher, Hövelmeyer, Nadine

Source: T-Helper Cells; 2014, p21-25, 5p

IL-1 receptor type I and type II differentially regulate EAE pathogenesis

Authors: Mufazalov, Ilgiz, Schelmbauer, Carsten, Kuschmann, Janina, Regen, Tommy, Hackenbruch, Christopher, Waisman, Ari

Source: In Journal of Neuroimmunology 15 October 2014 275(1-2):203-203

This result is not displayed to guests.
Login for full access.